Relief of Chronic or Resistant Depression (Re-ChORD): A pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression

被引:19
|
作者
Murray, Greg [2 ]
Michalak, Erin E. [1 ]
Axler, Auby [1 ]
Yaxley, David [1 ]
Hayashi, Brenda [1 ]
Westrin, Asa [3 ]
Ogrodniczuk, John S. [1 ]
Tam, Edwin M. [1 ]
Yatham, Lakshmi N. [1 ]
Lam, Raymond W. [1 ]
机构
[1] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada
[2] Swinburne Univ Technol, Fac Life & Social Sci, Melbourne, Vic, Australia
[3] Lund Univ, Dept Psychiat, S-22100 Lund, Sweden
基金
加拿大健康研究院;
关键词
Psychosocial treatments; Remission; Interpersonal psychotherapy; Occupational therapy; Chronic depression; BEHAVIORAL-ANALYSIS SYSTEM; DSM-IV; INTERPERSONAL PSYCHOTHERAPY; PRIMARY-CARE; PHARMACOTHERAPY; DISORDERS; NEFAZODONE; COMBINATION; MEDICATION; DYSTHYMIA;
D O I
10.1016/j.jad.2009.10.015
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Chronic depression is a particularly disabling mood disorder and treatment outcomes are poor with either psychotherapy or pharmacotherapy alone. There is growing evidence that an integrative treatment approach may be optimal. A novel multi-modal, multi-disciplinary treatment program, Re-ChORD, was developed at the University of British Columbia and evaluated in this pilot study. Methods: Re-ChORD consisted of guidelines-based medication management, and group-based interpersonal psychotherapy and occupational therapy. A randomized, parallel-groups, open-treatment trial was conducted comparing Re-ChORD to treatment as usual (TAU). Inclusion criteria were current depression (17-item Ham-D >= 15) and a diagnosis of a chronic depressive disorder. The primary outcome variable was clinical remission (17-item Ham-D <= 7) at 4 month assessment. Results: A total of 64 patients were randomised to Re-ChORD (N = 34) and TAU (N = 30). Under both intention to treat (ITT) and completer analyses, the remission rate was significantly higher in the Re-ChORD than TAU groups. Treatment effect size for remission was of medium magnitude (22.2% and 29.6% over TAU under ITT and completer analyses). Limitations: We did not collect sufficient follow-up data to investigate maintenance of gains. Re-ChORD shares elements with other combined treatments, and the present positive findings cannot be interpreted as being specific to the Re-ChORD program. Conclusions: Consistent with growing evidence that integrative treatments are necessary for chronic depressive disorders. Re-ChORD was demonstrated in this pilot study to produce significantly greater rates of remission than treatment as usual. A larger-scale trial is warranted. (C) 2009 Elsevier By. All rights reserved.
引用
收藏
页码:243 / 248
页数:6
相关论文
共 50 条
  • [21] Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial
    Ionescu, Dawn F.
    Bentley, Kate H.
    Eikermann, Matthias
    Taylor, Norman
    Johnson-Akeju, Oluwaseun
    Swee, Michaela B.
    Pavone, Kara J.
    Petrie, Samuel R.
    Dording, Christina
    Mischoulon, David
    Alpert, Jonathan E.
    Brown, Emery N.
    Baer, Lee
    Nock, Matthew K.
    Fava, Maurizio
    Cusin, Cristina
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 243 : 516 - 524
  • [22] Negative Effects of a Multimodal Inpatient CBASP Program: Rate of Occurrence and Their Impact on Treatment Outcome in Chronic and Treatment-Resistant Depression
    Herzog, Philipp
    Haeusler, Sophia
    Normann, Claus
    Brakemeier, Eva-Lotta
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [23] Evaluating an e-mental health program ("deprexis") as adjunctive treatment tool in psychotherapy for depression: Results of a pragmatic randomized controlled trial
    Berger, Thomas
    Krieger, Tobias
    Sude, Kerstin
    Meyer, Bjoern
    Maercker, Andreas
    JOURNAL OF AFFECTIVE DISORDERS, 2018, 227 : 455 - 462
  • [24] Evaluating an e-mental health program ("deprexis") as adjunctive treatment tool in psychotherapy for depression: design of a pragmatic randomized controlled trial
    Krieger, Tobias
    Meyer, Bjoern
    Sude, Kerstin
    Urech, Antoine
    Maercker, Andreas
    Berger, Thomas
    BMC PSYCHIATRY, 2014, 14
  • [25] Evaluating an e-mental health program (“deprexis”) as adjunctive treatment tool in psychotherapy for depression: design of a pragmatic randomized controlled trial
    Tobias Krieger
    Björn Meyer
    Kerstin Sude
    Antoine Urech
    Andreas Maercker
    Thomas Berger
    BMC Psychiatry, 14
  • [26] Sertraline hydrochloride treatment for patients with stable chronic obstructive pulmonary disease complicated with depression: a randomized controlled trial
    He, Yuanqiang
    Zheng, Yulong
    Xu, Chuanqin
    Yang, Haichen
    Wang, Ziyu
    Zhou, Liyang
    Wan, Yufeng
    Zheng, Donghui
    Zhu, Jing
    CLINICAL RESPIRATORY JOURNAL, 2016, 10 (03): : 318 - 325
  • [27] Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: analysis of a randomized trial
    Nishank Jain
    Fei Wan
    Monica Kothari
    Anuoluwapo Adelodun
    Jerry Ware
    Ravi Sarode
    S. Susan Hedayati
    BMC Nephrology, 20
  • [28] Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: analysis of a randomized trial
    Jain, Nishank
    Wan, Fei
    Kothari, Monica
    Adelodun, Anuoluwapo
    Ware, Jerry
    Sarode, Ravi
    Hedayati, S. Susan
    BMC NEPHROLOGY, 2019, 20 (01)
  • [29] An Open Label Study of COMP360 (Synthetic Psilocybin) in Treatment Resistant Depression With Chronic Active Suicidal Ideation
    Aaronson, Scott
    van der Vaart, Andrew
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 205 - 205
  • [30] A randomized controlled trial of Mindfulness-Based Cognitive Therapy (MBCT) versus treatment-as-usual (TAU) for chronic, treatment-resistant depression: study protocol
    Mira B. Cladder-Micus
    Janna N. Vrijsen
    Eni S. Becker
    Rogier Donders
    Jan Spijker
    Anne E. M. Speckens
    BMC Psychiatry, 15